2004
Phase I dose-escalation trial investigating the safety and tolerability of EPO906 plus gemcitabine in patients with advanced cancer
Rinehart J, Rothermel J, Anderson J, Lorusso P. Phase I dose-escalation trial investigating the safety and tolerability of EPO906 plus gemcitabine in patients with advanced cancer. Journal Of Clinical Oncology 2004, 22: 3100-3100. DOI: 10.1200/jco.2004.22.14_suppl.3100.Peer-Reviewed Original ResearchPhase I dose-escalation trialI dose-escalation trialDose-escalation trialAdvanced cancerEPO906TolerabilityGemcitabinePatientsCancerTrialsPhase I dose-escalation trial investigating the safety and tolerability of EPO906 plus gemcitabine in patients with advanced cancer
Rinehart J, Rothermel J, Anderson J, Lorusso P. Phase I dose-escalation trial investigating the safety and tolerability of EPO906 plus gemcitabine in patients with advanced cancer. Journal Of Clinical Oncology 2004, 22: 3100-3100. DOI: 10.1200/jco.2004.22.90140.3100.Peer-Reviewed Original ResearchPhase I dose-escalation trialI dose-escalation trialDose-escalation trialAdvanced cancerEPO906TolerabilityGemcitabinePatientsCancerTrials
2003
546 A phase I dose-escalation trial of ZD6126 administered as 5 daily dose every 3 weeks to patients with cancer refractory to other treatments
Budd G, Evelhoch J, Langmuir P, Veiero J, Shepherdson K, LoRusso P. 546 A phase I dose-escalation trial of ZD6126 administered as 5 daily dose every 3 weeks to patients with cancer refractory to other treatments. European Journal Of Cancer Supplements 2003, 1: s165. DOI: 10.1016/s1359-6349(03)90578-7.Peer-Reviewed Original ResearchPhase I dose-escalation trialI dose-escalation trialDose-escalation trialCancer refractoryDaily doseZD6126PatientsDoseTrialsWeeks